Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
Phase 2
Completed
- Conditions
- Coronary Heart Disease
- Registration Number
- NCT00130871
- Lead Sponsor
- Orion Corporation, Orion Pharma
- Brief Summary
The study evaluates the efficacy of intravenous levosimendan treatment started during a coronary artery bypass operation to wean patients from a heart lung machine.
- Detailed Description
Levosimendan or placebo infusion is started at the time of induction of anesthesia.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
- Three vessel coronary artery disease.
- Indication for on-pump coronary artery bypass surgery.
- Ejection fraction below 50%
Read More
Exclusion Criteria
- Indication for any cardiac valve surgery
- Previous coronary artery bypass surgery
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Proportion of successful primary weanings
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (2)
Helsinki University Central Hospital
🇫🇮Helsinki, Finland
Turku University Central Hospital
🇫🇮Turku, Finland